|
|
|||||||||||
*Devon Partnership NHS Trust,Wonford House, Exeter, Devon, e-mail: kompancariel.kuruvilla{at}devonptnrs.nhs.uk
Devon Partnership NHS Trust,Waverley House,Torquay
Devon Partnership NHS Trust, Kitson Hall,Torbay Hospital,Torquay, Devon
None. Funding detailed in Acknowledgements.
|
|
Abstract |
|---|
|
|
|---|
A questionnaire was sent by post to 185 psychiatrists in Devon and Cornwall to investigate training in the assessment and management of drug-related movement disorders and current training needs.
RESULTS
Responses were obtained from 143 psychiatrists (77%). Formal training wasreportedby 67 outof140 (48%). Only 26 out of 142 (18%) had received formal training in the use of rating scales, which were rarely used. The mean level of satisfaction with training received was below the mid-point on a 5-point scale at 2.76 (s.d.=1.23). Mean levels of confidence in the assessment and management of drug-related movement disorders were just above mid-point at 3.25 (s.d.=1.04) and 3.16 (s.d.=0.99) respectively. Specific training was thought to be necessary by 135 out of 141 psychiatrists (96%) and there were high levels of interest in further training, particularly from those below consultant grade.
CLINICAL IMPLICATIONS
Drug-related movement disorders affect patients' adherence to medication and their quality of life. Psychiatrists need more structured clinical training in assessing and managing these disorders in order to provide the best clinical care.
|
|
Introduction |
|---|
|
|
|---|
Studies from the USA and Canada suggest that doctors should increase their awareness of these disorders and require more training in their assessment and management (Hansen et al, 1992; Cortese et al, 2004). As anecdotal evidence suggested a similar situation in the UK, we conducted a survey of psychiatrists to assess previous training experiences, satisfaction with training, confidence in the assessment and management of drug-related movement disorders, and current training needs.
|
|
Method |
|---|
|
|
|---|
|
|
Results |
|---|
|
|
|---|
Training received in assessment
Of 140 respondents who answered the question, 67 (48%) had received formal
training in the assessment of drug-related movement disorders, for example,
seminar and/or tutorial. Of consultants, 45 ouf ot 60 (75%) were trained
compared with 14 out of 48 (29%) SHO/SpRs and 8 out of 32 associate
specialist/staff grade/CMOs (25%) (
2=31.13, d.f.=2, P<0.001).
Of the 65 who gave details about the amount of formal training received, 20
(31%) reported 1h or less, 30 (46%) reported half a day or less and 15 (23%)
indicated 1 day or more.
Of the 73 psychiatrists who had received no formal training, 49 (67%) had received informal training, with 33 reporting 1h or less. Multiple responses were allowed to indicate the main sources of informal training, which were consultants (94%) and self-teaching (33%). There were 24 psychiatrists who had received neither formal nor informal training in the assessment of drug-related movement disorders, representing 17% of the 140 who responded to this question.
Training and use of rating scales in assessment
Respondents were also asked about formal training, amount of use and
perceived utility of rating scales for assessment. Only 26 psychiatrists (18%)
had received any formal training in the use of the rating scales and the vast
majority (91%) used them rarely or not at all. On a scale of 1 (not very
useful) to 5 (very useful), the mean rating was 2.14 (s.d.=1.12).
Satisfaction with training received
Using a scale of 1 (dissatisfied) to 5 (very satisfied), the psychiatrists
gave ratings of their satisfaction with the amount and quality of their
training in the assessment of drug-related movement disorders
(Table 1). One-way analysis of
variance indicated a significant difference in the mean ratings of the three
groups in terms of their satisfaction with both the amount of training
received (F (2,132)=6.99, P=0.001) and its quality (F (2,127)=7.27, P=0.001).
Scheffé's post hoc test showed that on each rating the associate
specialist/staff grade/CMO group were less satisfied than the consultants.
|
Management
Of the 139 respondents providing details, 89 (64%) had had some formal
training in the management of drug-related movement disorders, with
consultants being more likely to have received training
(
2=12.50, d.f.=2, P<0.01). A majority of 68 (76%) reported
less than 1 day training, 12 (13%) 1-3 days and 9 (10%) more than 3 days. The
main sources of training were consultants (83%) and other staff
(26%); almost half of training was via courses and standard MRCPsych
teaching.
Levels of confidence in assessment and management
Using a scale of 1 (not very confident) to 5 (very confident), the
psychiatrists rated their confidence in assessing and managing drug-related
movement disorders (Table 2).
One-way analysis of variance indicated a significant difference in the mean
ratings of the three groups in terms of their confidence in both assessment (F
(2,139)=8.52, P=0.001) and management (F (2,138)=7.59, P=0.001).
Scheffé's post hoc test showed that for each item the SHO/SpRs group
were less confident than the consultants.
|
Training needs
Of 141 psychiatrists who answered the question, 135 (96%) thought that
specific training was required for drug-related movement disorders. Multiple
responses were allowed to indicate a possible range of professionals who
should provide the training. The responses of 128 psychiatrists were that
training should be given by: consultants, 95 (74%); SpRs, 60 (47%); other
staff, 43 (34%); associate specialist/staff grade/CMO, 27 (21%). Other
staff included comments that the training should be given by anyone
with the necessary expertise and interest. Of 53 consultants, 38 (72%) thought
that consultants should provide the training. There was agreement among all
grades that the training should be given early, that is, in the first 6 months
or the first year of the MRCPsych course.
Interest in receiving specific training
Using a scale of 1 (not very interested) to 5 (very interested),
psychiatrists were asked how interested they would be in receiving further
training in assessment of drug-related movement disorders by physical
examination or observation, assessment by use of rating scales and in
management (Table 3). One-way
analysis of variance showed a significant difference in the mean ratings of
the three groups for interest in further training: in assessment by
examination/observation (F (2,138)=11.54, P=0.001), assessment by rating
scales (F (2,135)=8.84, P=0.001) and management (F (2,136)=12.64, P=0.001).
Post hoc tests showed that, with the exception of training in the use of
rating scales, both the SHO/SpRs and the associate specialist/staff grade/CMO
groups were more interested in receiving further training than the
consultants.
|
|
|
Discussion |
|---|
|
|
|---|
Almost all of the respondents thought that specific training in the assessment and management of drug-related movement disorders should be given within the first year of the MRCPsych course. Consultants, SpRs or others with the necessary expertise and interest were the most frequently endorsed as potential sources of training. The highest levels of interest were shown by those below consultant grade, particularly for management of the disorders. It is possible that the relative lack of training and confidence among younger clinicians might be the result of a recent underemphasis on assessment and management of these side-effects, which has arisen from a misconception that the problem has been solved by the use of atypical antipsychotics.
The curriculum for the training of psychiatrists in the UK states that trainees should have an in depth knowledge of adverse drug reactions, including their prevalence and those that require appropriate corrective action. Clinical competency includes the ability to explain the effects and side-effects of medication to patients (Royal College of Psychiatrists, 2001). The clinical guidelines for schizophrenia produced by the National Institute for Clinical Excellence state that the clinician should monitor both therapeutic progress and tolerability of drugs on an ongoing basis, including screening for extrapyramidal side-effects such as tardive dyskinesia (National Institute for Clinical Excellence, 2002). These recommendations indicate that knowledge of the assessment and management of drug-related movement disorders is crucial.
Methodological limitations of our study include its retrospective design, with reliance on participants' memories of training and, because it was a postal survey, some data were missing. However, we had a good response rate and the results should reflect the training experiences and perceived training needs in Devon and Cornwall. We do not know to what extent these findings generalise to other parts of the UK. However, given that the training of psychiatrists is based on a standard curriculum (currently under review, Royal College of Psychiatrists, 2001), there are no obvious reasons why they should not.
|
|
Conclusion |
|---|
|
|
|---|
|
|
Acknowledgments |
|---|
|
|
References |
|---|
|
|
|---|
BARNES,T. R. E. & McPHILLIPS, M. A. (1996) Antipsychotic-induced extrapyramidal symptoms: role of anticholinergic drugs in treatment. CNS Drugs, 6, 315-330.
BROWNE, S., ROE, M., LANE, A., et al (1996) Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica, 94, 118 -124.[Medline]
CORTESE, L., JOG, M., McAULEY,T., et al (2004) Assessing and monitoring antipsychotic-induced movement disorders in hospitalized patients: a cautionary study. Canadian Journal of Psychiatry, 49, 31 -36.[Medline]
GERVIN, M. & BARNES,T. R. E. (2000) Assessment of
drug-related movement disorders in schizophrenia. Advances in
Psychiatric Treatment, 6, 332
-341.
HANSEN,T. E., BROWN,W. L., WEIGEL, R. M., et al (1992) Underrecognition of tardive dyskinesia and drug-induced parkinsonism by psychiatric residents. General Hospital Psychiatry, 14, 340 -344.[CrossRef][Medline]
MARDER, S. R. (2000) Schizophrenia: somatic treatment. In: Kaplan & Sadock's Comprehensive Textbook of Psychiatry (eds B. J. Sadock & V. A. Sadock), pp. 1199 -1210. Philadelphia: Lippincott Williams & Wilkins.
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (2002) Schizophrenia. Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care. London: NICE.
OWENS, D. G. C. (2000) Commentary. Advances
in Psychiatric Treatment, 6, 341
-343.
ROYAL COLLEGE OF PSYCHIATRISTS (2001) Curriculum for Basic Specialist Training and the MRCPsych Examination (Council Report CR95). London: Royal College of Psychiatrists.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| British Journal of Psychiatry | Advances in Psychiatric Treatment | All RCPsych Journals |